RESUMEN
Triamcinolone acetonide (TA) is an effective drug widely (off-label) used in the treatment of several ocular diseases involving inflammation and angiogenic processes. However, the use of TA ocular presents some limitations mainly related to its excipient composition, as in the case of benzyl alcohol. Thus, the aim of this work was to obtain an alternative TA formulation based on lipid nanocapsules (LNCs). Triamcinolone acetonide-loaded lipid nanocapsules (TA-LNCs) were obtained by the phase inversion temperature process without the use of irritating excipients, by combining lipids and surfactants generally recognized as safe. Pre-formulation studies were carried out to evaluate the TA solubility in different co-surfactants and to optimize the lipid core composition in order to enhance the drug loading and encapsulation rate in the LNCs. A stable final TA-LNC formulation was obtained with a mean particle size (MPS) of below 50â¯nm, a narrow size distribution (PDIâ¯<â¯0.2), a negative zeta potential (ZP) and a high encapsulation efficiency (%EEâ¯>â¯98%). In vitro cellular viability assays revealed that blank LNCs and TA-LNCs at 0.1⯵g/mL did not affect the viability of the human corneal epithelial (HCE) cells. TA-LNCs showed a high anti-inflammatory activity below the toxicity level, with a reduction of 30% in interleukin (IL)-6 secretion observed in an in vitro model using the same cell line. More importantly, the TA-LNCs revealed a therapeutic efficacy in the endotoxin-induced uveitis (EIU) rabbit model with a significant attenuation of clinical signs of an inflammatory response. These findings make the TA-LNCs a safer and more efficient alternative for the treatment of eye disorders.
Asunto(s)
Antiinflamatorios/administración & dosificación , Lípidos/química , Triamcinolona Acetonida/administración & dosificación , Uveítis/tratamiento farmacológico , Administración Oftálmica , Animales , Antiinflamatorios/farmacología , Línea Celular , Modelos Animales de Enfermedad , Estabilidad de Medicamentos , Epitelio Corneal/citología , Epitelio Corneal/efectos de los fármacos , Humanos , Masculino , Nanocápsulas , Tamaño de la Partícula , Conejos , Solubilidad , Tensoactivos/química , Temperatura , Triamcinolona Acetonida/farmacologíaRESUMEN
Human cystic echinococcosis is a zoonosis caused by the larval stage of the tapeworm Echinococcus granulosus sensu lato (s. l.). Although benzimidazole compounds such as albendazole (ABZ) and mebendazole have been the cornerstone of chemotherapy for the disease, there is often no complete recovery after treatment. Hence, new strategies are required to improve treatment of human cystic echinococcosis. The goals of the current study were as follows: (i) to evaluate the in vitro efficacy of the 5-fluorouracil (5-FU) and ABZ combination against E. granulosus s. l. protoscoleces and cysts, (ii) to compare the clinical efficacy of 5-FU alone or in combination with ABZ in infected mice. The combination of 5-FU+ABZ had a stronger in vitro effect against larval stage than that did both drugs alone. Even at the lowest concentration of 5-FU+ABZ combination (1µg/ml), the reduction of the viability of protoscoleces and cysts was greater than that observed with drugs alone at 10µg/ml. The results were confirmed at the ultrastructural level by scanning electron microscopy. These data helped to justify the in vivo investigations assessing the therapeutic potential of the combination of 5-FU and ABZ suspension in CF-1 mice infected with E. granulosus sensu stricto (s. s.) metacestodes. Treatment with 5-FU (10mg/kg) or 5-FU (10mg/kg) + ABZ suspension (5mg/kg) reduced the weight of cysts recovered from mice compared with control groups. Interestingly, the effect of 5-FU given weekly for 5 consecutive weeks was comparable to that observed with ABZ suspension under a daily schedule during 30days. Co-administration of 5-FU with ABZ did not enhance the in vivo efficacy of drugs alone calculated in relation to cysts weights. However, the combination provoked greater ultrastructural alterations compared to the monotherapy. In conclusion, we demonstrated the efficacy of 5-FU either alone or co-administrated with ABZ against murine experimental cystic echinococcosis. Since 5-FU treatments did not cause toxic effect in mice, further in vivo studies will be performed by adjusting the dosage and the frequency of treatments.
Asunto(s)
Albendazol/farmacología , Equinococosis/tratamiento farmacológico , Fluorouracilo/farmacología , Albendazol/administración & dosificación , Animales , Relación Dosis-Respuesta a Droga , Quimioterapia Combinada , Echinococcus granulosus/ultraestructura , Femenino , Fluorouracilo/administración & dosificación , RatonesRESUMEN
Ivermectin (IVM) is probably one of the most widely used antiparasitic drugs worldwide, and its efficacy is well established. However, slight differences in formulation may change the plasma kinetics, the biodistribution, and in consequence, the efficacy of this compound. The present study focuses on the development of a novel nanocarrier for the delivery of lipophilic drugs such as IVM and its potential application in antiparasitic control. Lipid nanocapsules (LNC) were prepared by a new phase inversion procedure and characterized in terms of size, surface potential, encapsulation efficiency, and physical stability. A complement activation assay (CH50) and uptake experiments by THP-1 macrophage cells were used to assess the stealth properties of this nanocarrier in vitro. Finally, a pharmacokinetics and biodistribution study was carried out as a proof of concept after subcutaneous (SC) injection in a rat model. The final IVM-LNC suspension displayed a narrow size distribution and an encapsulation rate higher than 90 % constant over the evaluated time (60 days). Through flow cytometry and blood permanence measurements, it was possible to confirm the ability of these particles to avoid the macrophage uptake. Moreover, the systemic disposition of IVM in the LNC administered by the SC route was higher (p < 0.05) (1367 ng h/ml) compared to treatment with a commercial formulation (CF) (1193 ng.h/ml), but no significant differences in the biodistribution pattern were found. In conclusion, this new carrier seems to be a promising therapeutic approach in antiparasitic control and to delay the appearance of resistance.
Asunto(s)
Antiparasitarios/uso terapéutico , Ivermectina/administración & dosificación , Lípidos/química , Nanocápsulas/química , Animales , Vías de Administración de Medicamentos , Portadores de Fármacos , Inyecciones Subcutáneas , Ivermectina/sangre , Ivermectina/farmacocinética , Macrófagos/metabolismo , Ratas , Distribución TisularRESUMEN
AIM & METHODS: The aim of the present work was to encapsulate paclitaxel (Ptx) in various lipid nanocapsules (LNCs) formulations and then to compare their pharmacokinetics and efficacy on a subcutaneous isograft model in rats. RESULTS: Three different Ptx formulations were obtained. Drug payloads ranged from 1.32 to 3.62 mg Ptx/g of formulation. After oral administration the area under concentration-time curve was higher (p < 0.05) if Ptx was encapsulated, (1,2 Distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(PEG)] (DSPE-PEG-NH2)) LNCs displaying the highest area under concentration-time curve (p < 0.05). Efficacy was better than control for standard LNCs after oral administration (p < 0.05) and for (DSPE-PEG-NH2) LNCs after intravenous administration. Despite good absorption, (DSPE-PEG-NH2) LNCs failed to remain efficient after oral route. CONCLUSION: This study highlights the importance of efficacy studies paired to pharmacokinetic studies for nanomedicines.
Asunto(s)
Antineoplásicos Fitogénicos/administración & dosificación , Glioma/tratamiento farmacológico , Nanocápsulas/química , Paclitaxel/administración & dosificación , Fosfatidiletanolaminas/química , Polietilenglicoles/química , Administración Oral , Aminación , Animales , Antineoplásicos Fitogénicos/farmacocinética , Antineoplásicos Fitogénicos/uso terapéutico , Línea Celular , Femenino , Glioma/patología , Humanos , Inyecciones Intravenosas , Paclitaxel/farmacocinética , Paclitaxel/uso terapéutico , Ratas , Ratas Endogámicas F344RESUMEN
Human cystic echinococcosis is a zoonosis caused by the metacestode stage of the tapeworm Echinococcus granulosus. Although benzimidazole compounds such as albendazole and mebendazole have been the cornerstone of chemotherapy for the disease, there is often no complete recovery after treatment. Hence, in searching for novel treatment options, we examined the in vitro efficacies of 5-fluorouracil (5-FU) and paclitaxel (PTX) against E. granulosus germinal cells, protoscoleces and cysts. 5-FU or PTX inhibited the growth of E. granulosus cells in a time dependent manner. Although both treatments had a protoscolicidal effect, 5-FU had a considerably stronger effect than PTX. 5-FU produced a dose- and time-dependent effect, provoking the complete loss of viability after 24 days of incubation. Moreover, cysts did not develop following the inoculation of treated protoscoleces into mice. The loss of viability was slower in PTX treated protoscoleces, reaching to approximately 60% after 30 days. The results of the in vitro treatment with 5-FU and PTX were similar in secondary murine cysts. The employment of SEM and TEM allowed us to examine, at an ultrastructural level, the effects induced by 5-FU and PTX on E. granulosus germinal cells, protoscoleces and murine cysts. In conclusion, the data obtained clearly demonstrated that 5-FU and PTX at clinically achievable concentrations inhibit the survival of larval cells, protoscoleces and metacestodes. In vivo studies to test the antiparasitic activities of 5-FU and PTX are currently being undertaken on the murine model of cystic echinococcosis.
Asunto(s)
Anticestodos/farmacología , Echinococcus granulosus/efectos de los fármacos , Fluorouracilo/farmacología , Paclitaxel/farmacología , Animales , Relación Dosis-Respuesta a Droga , Equinococosis/tratamiento farmacológico , Femenino , Técnicas In Vitro , Larva/efectos de los fármacos , Ratones , Ratones EndogámicosRESUMEN
The determination of the nanocarrier fate in preclinical models is required before any translation from laboratory to clinical trials. Modern fluorescent imaging techniques have gained considerable advances becoming a powerful technology for non-invasive visualization in living subjects. Among them, Forster (fluorescence) resonance energy transfer (FRET) is a particular fluorescence imaging which involves energy transfer between 2 fluorophores in a distance-dependent manner. Considering this feature, the encapsulation of an acceptor/donor pair in lipid nanoparticles (LNEs: lipid nanoemulsions, LNCs: lipid nanocapsules) allowed the carrier integrity to be tracked. Accordingly, we used this FRET technique to evaluate the behavior of LNEs, conventional LNCs and newly designed stealth LNCs. After the development through a one-step (OS) PEGylation process of these stealth LNCs (OS LNCs), in vitro guest exchange dynamics and release kinetics were evaluated for both LNC formulations. We thereafter assessed in vivo biodistribution of all types of lipid nanoparticles. Results showed enhanced stability of encapsulation in OS LNCs in comparison to conventional LNCs. Additionally, the presence of the long PEG chains on the lipid nanoparticle surface altered the biodistribution pattern. Despite different release kinetic profiles, OS LNCs and LNEs showed extended blood circulation time associated with a good structure stability over several hours after intravenous injection.
Asunto(s)
Transferencia Resonante de Energía de Fluorescencia/métodos , Colorantes Fluorescentes/administración & dosificación , Lípidos/química , Nanocápsulas/química , Imagen Óptica/métodos , Animales , Portadores de Fármacos/química , Femenino , Colorantes Fluorescentes/farmacocinética , Ratones Desnudos , Polietilenglicoles/química , Distribución TisularRESUMEN
Plasmid DNA (pDNA) and small interfering RNAs (siRNAs) are very useful tools for the treatment of cancer. However, pDNA and siRNAs efficacy is restricted by their negative charge and susceptibility to degradation by endonucleases that prevent them penetrating tissue and cellular barriers such as the plasma and endolysosomal membranes. Viral vectors have some advantages but their use is largely limited by their immunogenicity. On the other hand, synthetic nanoparticles have advantage of being relatively non-immunogenic but their ability to deliver nucleic acids remains less efficient than their viral counterparts. The present study is focussed on the development and evaluation of biomimetic lipid nanocapsules (LNCs) functionalized with a L1 papillomavirus type-16 capsid-derived lipopeptide on their surface, for transfection of U87MG glioma cells and Caco-2 colorectal adenocarcinoma cells with pDNA or siRNAs. Since the L1-peptide has been described as a nuclear localization signal able to complex with nucleic acids and bind to heparan sulfate on the cell surface, the structure and function of L1-peptide bound to LNCs (L1-LNCs) were investigated. Although L1-LNCs were shown to complex with both pDNA and siRNAs, the pDNA-L1-LNC complexes showed only weak transfection efficiency. In contrast, siRNA-L1-LNC complexes appeared as effective repressors of targeted messengers.
Asunto(s)
Proteínas de la Cápside/química , ADN/química , Lipopéptidos/química , Nanocápsulas/química , Proteínas Oncogénicas Virales/química , ARN Interferente Pequeño/química , Antígeno AC133 , Animales , Antígenos CD/genética , Células COS , Proteínas de la Cápside/administración & dosificación , Línea Celular Tumoral , Chlorocebus aethiops , ADN/administración & dosificación , Glicoproteínas/genética , Humanos , Lípidos/química , Lipopéptidos/administración & dosificación , Nanocápsulas/administración & dosificación , Neoplasias/genética , Neoplasias/metabolismo , Proteínas Oncogénicas Virales/administración & dosificación , Péptidos/genética , Plásmidos , Proteínas Proto-Oncogénicas c-bcl-2/genética , ARN Interferente Pequeño/administración & dosificaciónRESUMEN
The assessment of tumor oxygenation is a crucial factor in cancer therapy and may be carried out using fluorine MRI once fluorine probes have been distributed within the tumor. However, the deposit of those highly fluorinated compounds often jeopardizes anatomical image quality and requires emulsification of the probes. Due to the high density and the high lipophilicity of perfluorocarbons, nanoemulsion of these molecules usually requires high-energy processes. In the present work, we discuss the synthesis and the physico-chemical characterization of perfluorocarbon nanocapsules using a low-energy phase-inversion process. The nanocapsules were tested on a mouse tumor brain model to assess oxygenation.
Asunto(s)
Fluorocarburos/química , Lípidos/química , Nanocápsulas/química , Neoplasias/metabolismo , Oxígeno/química , Animales , Encéfalo/metabolismo , Encéfalo/patología , Calibración , Línea Celular Tumoral , Flúor/química , Radioisótopos de Flúor/farmacología , Imagen por Resonancia Magnética , Masculino , Ratones , Ratones SCID , Nanopartículas/química , Temperatura , Factores de TiempoRESUMEN
The use of hybrid pH-sensitive micelles based mainly on the (PEO)(129)(P2VP)(43)(PCL)(17) ABC miktoarm star copolymer as potential triggered drug delivery systems was investigated. Co-micellization of this star copolymer with a second copolymer labeled by a targeting ligand, i.e. biotin, on the pH sensitive block (poly-2-vinylpyridine) is considered here in order to impart possible active targeting of the tumor cells. Two architectures were studied for these labeled copolymers, i.e. a miktoarm star or a linear ABC terpolymer, and the respective hybrid micelles are compared in terms of cytotoxicity (cells viability) and cellular uptake (using fluorescent dye loaded micelles). Finally, the triggered drug release in the cytosol of tumor cells was investigated by studying, on the one hand, the lysosomal integrity after internalization and, on the other hand, the release profile in function of the pH.
Asunto(s)
Portadores de Fármacos/farmacología , Micelas , Nanopartículas/química , Animales , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Portadores de Fármacos/síntesis química , Portadores de Fármacos/química , Concentración de Iones de Hidrógeno , Interacciones Hidrofóbicas e Hidrofílicas , Lisosomas/metabolismo , Polivinilos/química , Polivinilos/farmacología , RatasRESUMEN
In the context of targeted therapy, we addressed the possibility of developing a drug delivery nanocarrier capable to specifically reach cancer cells that express the most prominent marker associated with cancer stem cell (CSC) phenotype, AC133. For this purpose, 100nm lipid nanocapsules (LNCs) were functionalized with a monoclonal antibody (mAb) directed against AC133 according to two distinct methods: firstly, post-insertion within 100nm LNCs of a lipid poly(ethylene glycol) functionalized with reactive-sulfhydryl maleimide groups (DSPE-PEG(2000)-maleimide) followed by thiolated mAb coupling, and, secondly, creation of a thiolated lipo-immunoglobulin between DSPE-PEG(2000)-maleimide and AC133, then post-inserted within LNCs. Due to the reduced number of purification steps, lower amounts of DSPE-PEG(2000)-maleimide that were necessary as well as lower number of free maleimide functions present onto the surface of immuno-LNC, the second method was found to be more appropriate. Thus, 126nm AC133-LNC with a zeta potential of -22mV while keeping a narrow distribution were developed. Use of the IgG1κ isotype control-immunoglobulins produced similar control IgG1-LNCs. Micro-Bradford colorimetric assay indicated a fixation of about 40 immunoglobulins per LNC. Use of human Caco-2 cells that constitutively express AC133 (Caco-2-AC133(high)) allowed addressing the behavior of the newly functionalized immuno-LNCs. siRNA knockown strategy permitted to obtain Caco-2-AC133(low) for comparison. Immunofluorescence-combined flow cytometry analysis demonstrated that the epitope-recognition function of AC133 antibody was preserved when present on immuno-LNCs. Although grafting of immunoglobulins onto the surface of LNCs repressed their internalization within Caco-2 cells as evaluated by flow cytometry, AC133-specific cellular binding was obtained with AC133-LNC as assessed by computer-assisted fluorescence microscopy. In conclusion, interest of AC133-LNCs as niche carriers is discussed toward the development of CSC targeted chemo- or radio-nanomedicines.
Asunto(s)
Anticuerpos Monoclonales/inmunología , Antígenos CD/inmunología , Antígenos de Neoplasias/inmunología , Sistemas de Liberación de Medicamentos/métodos , Glicoproteínas/inmunología , Nanocápsulas/química , Nanoconjugados/química , Péptidos/inmunología , Antígeno AC133 , Anticuerpos Monoclonales/química , Anticuerpos Monoclonales/metabolismo , Anticuerpos Monoclonales/farmacología , Reacciones Antígeno-Anticuerpo/inmunología , Antígenos CD/genética , Antígenos CD/metabolismo , Antígenos de Neoplasias/genética , Antígenos de Neoplasias/metabolismo , Células CACO-2 , Adhesión Celular/efectos de los fármacos , Membrana Celular/metabolismo , Citoplasma/metabolismo , Endocitosis/fisiología , Glicoproteínas/genética , Glicoproteínas/metabolismo , Humanos , Imidoésteres/química , Lecitinas/química , Maleimidas/química , Tamaño de la Partícula , Péptidos/genética , Péptidos/metabolismo , Fosfatidiletanolaminas/química , Polietilenglicoles/química , ARN Interferente Pequeño/genética , Electricidad Estática , Ácidos Esteáricos/química , Compuestos de Sulfhidrilo/síntesis química , Propiedades de Superficie , Triglicéridos/químicaRESUMEN
The aim of this work was to develop a new microparticulate system able to form a complex with radionuclides with a high yield of purity for diagnostic or therapeutic applications. Owing to its properties potato starch was chosen as starting material and modified by oxidization and coupling of a ligand (polyamine) enabling modified starch to chelate radionuclides. The choice of suitable experiments was based on a combination of a Rechtschaffner experimental design and a surface response design to determine the influence of experimental parameters and to optimize the final product. Starch-based microparticle formulations from the experimental plans were compared and characterized through particle size analysis, scanning electron microscopy, elemental analysis and, for the most promising formulations, by in vitro labeling stability studies and determination of free polyamine content or in vivo imaging studies. The mechanism of starch-based microparticle degradation was identified by means of size measurements. The results of the Rechtschaffner design showed the positive qualitative effect of the temperature and the duration of coupling reaction whereas surface response analysis clearly showed that, by increasing the oxidization level and starch concentration, the nitrogen content in the final product is increased. In vitro and in vivo characterization led to identification of the best formulation. With a size around 30 µm, high radiochemical purity (over 95%) and a high signal-to-noise ratio (over 600), the new starch-based microparticulate system could be prepared as ready-to-use kits and sterilized without modification of its characteristics, and thus meet the requirement for in vivo diagnostic and therapeutic applications.
Asunto(s)
Microesferas , Medicina Nuclear/métodos , Almidón/uso terapéutico , Análisis de Varianza , Animales , Cadaverina/metabolismo , Cromatografía Líquida de Alta Presión , Masculino , Oxidación-Reducción , Tamaño de la Partícula , Ratas , Ratas Wistar , Reproducibilidad de los Resultados , Coloración y Etiquetado , Almidón/química , Almidón/ultraestructura , Esterilización , Estrés Mecánico , Propiedades de SuperficieRESUMEN
Evaluation of the biocompatibility of pH-triggered targeting micelles was performed with the goal of studying the effect of a poly(ethylene oxide) (PEO) coating on micelle stealth properties. Upon protonation under acidic conditions, pH-sensitive poly(2-vinylpyridine) (P2VP) blocks were stretched, exhibiting positive charges at the periphery of the micelles as well as being a model targeting unit. The polymer micelles were based on two different macromolecular architectures, an ABC miktoarm star terpolymer and an ABC linear triblock copolymer, which combined three different polymer blocks, i.e. hydrophobic poly(ε-caprolactone), PEO and P2VP. Neutral polymer micelles were formed at physiological pH. These systems were tested for their ability to avoid macrophage uptake, their complement activation and their pharmacological behavior after systemic injection in mice, as a function of their conformation (neutral or protonated). After protonation, complement activation and macrophage uptake were up to twofold higher than for neutral systems. By contrast, when P2VP blocks and the targeting unit were buried by the PEO shell at physiological pH, micelle stealth properties were improved, allowing their future systemic injection with an expected long circulation in blood. Smart systems responsive to pH were thus developed which therefore hold great promise for targeted drug delivery to an acidic tumoral environment.
Asunto(s)
Sistemas de Liberación de Medicamentos/métodos , Micelas , Polietilenglicoles/química , Animales , Línea Celular , Fenómenos Químicos/efectos de los fármacos , Activación de Complemento/efectos de los fármacos , Fluorescencia , Humanos , Concentración de Iones de Hidrógeno/efectos de los fármacos , Inyecciones Intravenosas , Cinética , Macrófagos/efectos de los fármacos , Macrófagos/metabolismo , Ratones , Polietilenglicoles/administración & dosificación , Polietilenglicoles/farmacocinética , Polietilenglicoles/farmacología , Rodaminas/metabolismoRESUMEN
Taking advantage from the development of SV30, a new analogue of the pro-apoptotic molecule HA14-1, the aim of this study was to functionally evaluate SV30 and to develop safe nanocarriers for its administration. By using an inversion phase process, 57nm organic solvent-free lipid nanocapsules loaded with SV30 (SV30-LNCs) were formulated. Biological performance of SV30 and SV30-LNCs were evaluated on F98 cells that express Bax and Bcl-2, through survival assays, HPLC, flow cytometry, confocal microscopy and spectral imaging. We observed that SV30 alone or in combination with paclitaxel, etoposide or beam radiation could trigger cell death in a similar fashion to HA14-1. Although partially blocked by Z-VAD-fmk, this effect was coincident to caspase-3 activation. Hence, we established that SV30-LNCs improved SV30 biological activity together with a potentiation of the mitochondrial membrane potential decrease. Interestingly, flow cytometry and confocal analysis indicated that SV30 itself conferred to LNCs improved mitochondrial targeting skills that may present a great interest toward the development of mitochondria targeted nanomedicines.
Asunto(s)
Antineoplásicos/administración & dosificación , Antineoplásicos/farmacocinética , Benzopiranos/química , Glioma/tratamiento farmacológico , Lípidos/química , Mitocondrias/metabolismo , Nanocápsulas/química , Nitrilos/química , Proteínas Proto-Oncogénicas c-bcl-2/antagonistas & inhibidores , Animales , Antineoplásicos/farmacología , Caspasa 3/metabolismo , Línea Celular Tumoral , Mitocondrias/efectos de los fármacos , RatasRESUMEN
We evaluated the safety and the efficacy of doxorubicin drug eluting beads "CM-BC1" when used locally in a 9L glioma model. Twenty microlitres of 1mg/ml CM-BC1 (4µg/rat), 10mg/ml CM-BC1 (40µg/rat) or unloaded beads were injected into the brain of 27 rats which was analyzed on day 8, month 3 or month 6. Then, after tumor implantation, rats were treated locally: (1) control group; (2) a group receiving 20µl of unloaded beads, (3) a group "3×6Gy whole-brain irradiation" (WBI), (4) a group receiving 20µl of 1mg/ml CM-BC1 and (5) a group receiving 20µl of 1mg/ml CM-BC1 followed by a WBI. Both the unloaded beads and the lower dose of 1mg/ml CM-BC1 were well tolerated with no early deaths in opposite to 10mg/ml CM-BC1. Medians of survival for the "1mg/ml CM-BC1" group and the combination group are respectively 28.9 and 64.4 days. These results were significant compared to the "unloaded beads" group. The rat's survival was not significantly improved in comparison with the radiotherapy group. This preliminary evidence suggests that 1mg/ml CM-BC1 could be interesting for recurrent high-grade gliomas. Further work is necessary to improve this seducing tool.
Asunto(s)
Antibióticos Antineoplásicos/farmacología , Neoplasias Encefálicas/tratamiento farmacológico , Doxorrubicina/farmacología , Glioma/tratamiento farmacológico , Animales , Antibióticos Antineoplásicos/administración & dosificación , Antibióticos Antineoplásicos/toxicidad , Neoplasias Encefálicas/patología , Neoplasias Encefálicas/radioterapia , Línea Celular Tumoral , Terapia Combinada , Relación Dosis-Respuesta a Droga , Doxorrubicina/administración & dosificación , Doxorrubicina/toxicidad , Implantes de Medicamentos , Femenino , Glioma/patología , Glioma/radioterapia , Ratas , Ratas Endogámicas F344 , Ratas Wistar , Sobrevida , Factores de TiempoRESUMEN
Lipid nanocapsules (LNCs) have been shown to improve paclitaxel (Ptx) bioavailability and transport across an intestinal barrier model. In the present study, the interaction between P-glycoprotein (P-gp) and LNC transport across Caco-2 cells are investigated. Transport experiments have been performed on Caco-2 cells displaying different P-gp activities (early and later cell passages). The permeability of Ptx encapsulated in LNCs has been studied in the presence of P-gp inhibitors (verapamil and vinblastin) or unloaded LNCs. The uptake of dye-labelled LNCs was also observed in the presence of the same inhibitors. It was found that the permeability of Ptx varied depending on the passages with later ones showing higher absolute values (5.74+/-1.21 cms(-1) vs 133.41+/-5.74 cms(-1)). P-gp inhibition obtained with verapamil or vinblastin improved Ptx transport up to 98%. LNCs have also demonstrated their capacity to increase their own transport. Experiments performed with dye-labelled LNCs demonstrated an enhancement of the uptake of dye (Nile red), only in the presence of verapamil. These results demonstrated an effect of P-gp on the transport of Ptx when loaded in LNCs and support a direct effect of P-gp on their endocytosis in Caco-2 cells. These finding may assist in the development of new nanomedicine for oral administration.
Asunto(s)
Miembro 1 de la Subfamilia B de Casetes de Unión a ATP/metabolismo , Antineoplásicos Fitogénicos/farmacocinética , Portadores de Fármacos , Mucosa Intestinal/metabolismo , Nanocápsulas , Paclitaxel/farmacocinética , Administración Oral , Antineoplásicos Fitogénicos/química , Antineoplásicos Fitogénicos/metabolismo , Disponibilidad Biológica , Transporte Biológico , Células CACO-2 , Permeabilidad de la Membrana Celular , Composición de Medicamentos , Endocitosis , Humanos , Paclitaxel/química , Paclitaxel/metabolismoRESUMEN
Incomplete protein release from PLGA-based microspheres due to protein interactions with the polymer is one of the main issues in the development of PLGA protein-loaded microspheres. In this study, a two-dimensional adsorption model was designed to rapidly assess the anti-adsorption effect of formulation components (additives, additives blended with the polymer or modified polymers). Lysozyme was chosen as a model protein because of its strong, non-specific adsorption on the PLGA surface. This study showed that PEGs, poloxamer 188 and BSA totally inhibited protein adsorption onto the PLGA37.5/25 layer. Similarly, it was emphasised that more hydrophilic polymers were less prone to protein adsorption. The correlation between this model and the in vitro release profile was made by microencapsulating lysozyme with a low loading in the presence of these excipients by a non-denaturing s/o/w encapsulation technique. The precipitation of lysozyme with the amphiphilic poloxamer 188 prior to encapsulation exhibited continuous release of active lysozyme over 3 weeks without any burst effect. To promote lysozyme release in the latter stage of release, a PLGA-PEG-PLGA tribloc copolymer was used; lysozyme was continuously released over 45 days in a biologically active form.
Asunto(s)
Portadores de Fármacos/química , Excipientes/química , Ácido Láctico/química , Muramidasa/administración & dosificación , Ácido Poliglicólico/química , Adsorción , Animales , Bovinos , Precipitación Química , Preparaciones de Acción Retardada , Emulsiones , Microesferas , Muramidasa/química , Poloxámero/química , Polietilenglicoles/química , Copolímero de Ácido Poliláctico-Ácido Poliglicólico , Polímeros/química , Albúmina Sérica Bovina/química , Factores de TiempoRESUMEN
The use of lipid nanocapsules (LNCs) has enabled an improvement of the oral bioavailability of paclitaxel (Ptx). However, mechanisms that support this recent observation are not yet understood. By focusing on the well defined in vitro Caco-2 model, the purpose of this study was to evaluate the transport of LNCs across a model intestinal barrier. Firstly, four sizes of paclitaxel or dye (Nile Red)-loaded LNCs were formulated and LNCs with sizes between 26.3+/-2.7 nm and 132.7+/-5.5 nm were obtained. Different transport and uptake experiments were then performed across a Caco-2 cells culture model using these LNCs. Paclitaxel-loaded LNCs improved permeability of Ptx across intestinal epithelium compared with free Ptx or Taxol by a factor of 3.5. At 37 degrees C particle size did not influence transport efficiency. However, at 4 degrees C a decrease in Ptx transport was observed with increasing size of LNCs. Thus, with LNCs of 25 nm size, the apparent permeability coefficient (P(app)) was 5.3+/-1.1 cm s(-1) at 37 degrees C and 2.2+/-0.4 cm s(-1) at 4 degrees C. In comparison in LNCs of 130 nm size, the P(app) decreased from 5.8+/-0.8 cm s(-1) at 37 degrees C to 0.5+/-0.1 cm s(-1) at 4 degrees C. The uptake of LNCs by Caco-2 cells and the incapacity of LNCs to open tight junctions were also demonstrated. Furthermore, experiment transports were performed in the presence of different inhibitors of endocytosis. Findings indicated a reduction of Ptx transport of 30+/-6% when cell cholesterol was depleted, 65+/-12% when caveolae-mediated endocytosis was inhibited and 20+/-8% when clathrin-mediated endocytosis was inhibited. Finally, transmission electronic microscopy showed the presence of nano-objects on the basolateral side of the Caco-2 cell monolayers when LNCs were applied on the apical side.
Asunto(s)
Antineoplásicos Fitogénicos/metabolismo , Portadores de Fármacos , Endocitosis , Absorción Intestinal , Mucosa Intestinal/metabolismo , Lípidos/química , Nanocápsulas , Paclitaxel/metabolismo , Antineoplásicos Fitogénicos/química , Células CACO-2 , Caveolas/metabolismo , Permeabilidad de la Membrana Celular , Química Farmacéutica , Colesterol/metabolismo , Vesículas Cubiertas por Clatrina/metabolismo , Composición de Medicamentos , Humanos , Mucosa Intestinal/ultraestructura , Cinética , Paclitaxel/química , Tamaño de la Partícula , Temperatura , Uniones Estrechas/metabolismoRESUMEN
The in vitro gastrointestinal stability of lipid nanocapsules (LNCs) was studied in different media. The size of LNCs was determined in simulated gastric and intestinal media. In updated fasted state simulated intestinal fluid (FaSSIF-V2) and updated fed state simulated intestinal fluid (FeSSIF-V2) media, the encapsulation ratio of paclitaxel-loaded LNCs was also measured. The size of LNCs was not modified after 3h in simulated gastric fluid and simulated intestinal fluid described by the United States Pharmacopeia, in FaSSIF, FaSSIF-V2, and in FeSSIF. Moreover, in the presence of pancreatin in FeSSIF-V2, a decreased above 30% of the loading of paclitaxel was observed. This was attributed to the presence of lipase in pancreatin that could interact with Lipoid (a mixture of phosphatidylcholine and phosphatidylethanolamine), present on the shell of LNC. As a conclusion, LNCs were stable on gastric medium and fasted state intestinal medium.
Asunto(s)
Jugo Gástrico , Secreciones Intestinales , Lípidos/química , Nanocápsulas/química , Estabilidad de Medicamentos , Jugo Gástrico/metabolismo , Tracto Gastrointestinal/metabolismo , Secreciones Intestinales/metabolismo , Lípidos/fisiología , SolubilidadRESUMEN
The main objective of gene therapy via a systemic pathway is the development of a stable and non-toxic gene vector that can encapsulate and deliver foreign genetic materials into specific cell types with the transfection efficiency of viral vectors. With this objective, DNA complexed with cationic lipids of DOTAP/DOPE was encapsulated into lipid nanocapsules (LNCs) forming nanocarriers (DNA LNCs) with a size suitable for systemic injection (109+/-6 nm). With the goal of increasing systemic delivery, LNCs were stabilised with long chains of poly(ethylene glycol) (PEG), either from a PEG lipid derivative (DSPE-mPEG(2000)) or from an amphiphilic block copolymer (F108). In order to overcome internalisation difficulties encountered with PEG shield, a specific ligand (galactose) was covalently added at the distal end of the PEG chains, in order to provide active targeting of the asialoglycoprotein-receptor present on hepatocytes. This study showed that DNA LNCs were as efficient as positively charged DOTAP/DOPE lipoplexes for transfection. In primary hepatocytes, when non-galactosylated, the two polymers significantly decreased the transfection, probably by creating a barrier around the DNA LNCs. Interestingly, galactosylated F108 coated DNA LNCs led to a 18-fold increase in luciferase expression compared to non-galactosylated ones.
Asunto(s)
ADN/química , Galactosa/química , Marcación de Gen/métodos , Hepatocitos/fisiología , Lípidos/química , Nanocápsulas/química , Animales , Células Cultivadas , ADN/administración & dosificación , ADN/genética , Galactosa/administración & dosificación , Galactosa/genética , Células HeLa , Hepatocitos/efectos de los fármacos , Humanos , Lípidos/administración & dosificación , Lípidos/genética , Masculino , Ratones , Nanocápsulas/administración & dosificación , RatasRESUMEN
In many cell-culture and animal models, the therapeutic effects of the entrapped drugs in lipid nanocapsules (LNCs) were preserved with low toxicity. These results allow foreseeing further preclinical efficiency and toxicity studies in animals. In this article, preliminary studies were performed to check the genetically modified organism (GMO) status of the LNCs components and to determine the effects of the acidity of the LNCs dispersions in acid-base balance in rats. Then, several freezing protocols to store paclitaxel-loaded LNCs dispersions for a 6-month period were compared. Results indicate that the Lipoïd S75-3 could not be certified GMO-free. The same soya bean lecithin certified to be GMO-free permitted to produce LNCs with expected characteristics. The blood administration of blank LNCs dispersions in rats induced no modifications of blood acidity, but a significant decrease of the base excess was observed. Injections of LNCs dispersions in animals might induce iatrogenic acidosis. We finally demonstrated that the best protocol to store LNCs dispersion for a 6-month period is by freezing in liquid nitrogen. This protocol minimized the characteristics modifications and interrupted the drug-release phenomenon. These original data are expected to prepare of LNCs dispersions well adapted for i.v. administration in animals.